Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
- Written by PR Newswire
- Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4
- Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments
- Additional royalties to be paid based on net sales following...
